News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tobira Therapeutics Inc. Receives Additional US Patent on Cenicriviroc



10/26/2012 7:37:09 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tobira Therapeutics, Inc., developer of innovative antiretroviral therapies for HIV, today announced the United States Patent and Trademark Office has issued patent 8,183,273, claiming compositions of matter of a broad family of compounds with activity against chemokine receptors CCR5 and CCR2. The most advanced drug candidate in this family of compounds, Tobira’s cenicriviroc, is currently in Phase 2b clinical evaluation for the treatment of HIV-1 infection. This is the second composition of matter patent issued to Tobira in the United States, expanding coverage of Tobira’s portfolio of chemokine inhibitors.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES